Strides Pharma Science Management
Management criteria checks 2/4
Strides Pharma Science's CEO is Badree Komandur, appointed in Jun 2024, has a tenure of less than a year. total yearly compensation is ₹44.00M, comprised of 83% salary and 17% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth ₹17.06M. The average tenure of the management team and the board of directors is 0.5 years and 6.3 years respectively.
Key information
Badree Komandur
Chief executive officer
₹44.0m
Total compensation
| CEO salary percentage | 83.0% |
| CEO tenure | less than a year |
| CEO ownership | 0.03% |
| Management average tenure | less than a year |
| Board average tenure | 6.3yrs |
Recent management updates
Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01
Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹2b |
| Jun 30 2024 | n/a | n/a | -₹475m |
| Mar 31 2024 | ₹44m | ₹37m | -₹1b |
| Dec 31 2023 | n/a | n/a | -₹2b |
| Sep 30 2023 | n/a | n/a | -₹2b |
| Jun 30 2023 | n/a | n/a | -₹924m |
| Mar 31 2023 | ₹44m | ₹36m | -₹2b |
| Dec 31 2022 | n/a | n/a | -₹2b |
| Sep 30 2022 | n/a | n/a | -₹2b |
| Jun 30 2022 | n/a | n/a | -₹4b |
| Mar 31 2022 | ₹46m | ₹38m | -₹5b |
| Dec 31 2021 | n/a | n/a | -₹4b |
| Sep 30 2021 | n/a | n/a | -₹3b |
| Jun 30 2021 | n/a | n/a | -₹543m |
| Mar 31 2021 | ₹44m | ₹33m | ₹3b |
| Dec 31 2020 | n/a | n/a | ₹28m |
| Sep 30 2020 | n/a | n/a | ₹589m |
| Jun 30 2020 | n/a | n/a | ₹1b |
| Mar 31 2020 | ₹37m | ₹23m | ₹492m |
| Dec 31 2019 | n/a | n/a | ₹3b |
| Sep 30 2019 | n/a | n/a | ₹2b |
| Jun 30 2019 | n/a | n/a | ₹745m |
| Mar 31 2019 | ₹32m | ₹18m | ₹840m |
| Dec 31 2018 | n/a | n/a | -₹93m |
| Sep 30 2018 | n/a | n/a | ₹139m |
| Jun 30 2018 | n/a | n/a | ₹415m |
| Mar 31 2018 | ₹26m | ₹17m | ₹544m |
Compensation vs Market: Badree's total compensation ($USD517.88K) is above average for companies of similar size in the Indian market ($USD352.86K).
Compensation vs Earnings: Badree's compensation has been consistent with company performance over the past year.
CEO
Badree Komandur (52 yo)
less than a year
Tenure
₹44,000,000
Compensation
Mr. Badree Komandur had been the Chief Financial Officer and Executive Director of Finance of Strides Pharma Science Limited (formerly known as Strides Shasun Limited) since August 1, 2013 until June 1, 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairperson | 34.5yrs | ₹120.00m | 2.11% ₹ 1.3b | |
| MD & Group CEO | less than a year | ₹44.00m | 0.027% ₹ 17.1m | |
| Compliance Officer & Company Secretary | 7.8yrs | ₹6.85m | no data | |
| Executive Director of Business Development & Director | less than a year | ₹7.50m | 0.064% ₹ 39.9m | |
| Group CFO & Chief Investor Relations Officer | less than a year | no data | no data | |
| Chief Operating Officer | less than a year | no data | no data | |
| Group General Counsel | no data | no data | no data | |
| Group Chief Human Resource Officer | no data | no data | no data | |
| Executive Vice President of Operations | no data | no data | no data | |
| Senior Vice President of Strides Pharma Inc. | no data | no data | no data | |
| Chief Quality Officer | no data | no data | no data | |
| Chief Information Technology Officer | no data | no data | no data |
0.5yrs
Average Tenure
48yo
Average Age
Experienced Management: STAR's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Executive Chairperson | 34.5yrs | ₹120.00m | 2.11% ₹ 1.3b | |
| MD & Group CEO | 7.6yrs | ₹44.00m | 0.027% ₹ 17.1m | |
| Executive Director of Business Development & Director | less than a year | ₹7.50m | 0.064% ₹ 39.9m | |
| Independent Director | 7.6yrs | ₹4.00m | no data | |
| Executive Chairman of Arrow Pharmaceuticals Pty Ltd | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | ₹4.00m | 0.0024% ₹ 1.5m | |
| Independent Director | less than a year | ₹800.00k | no data |
6.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: STAR's board of directors are considered experienced (6.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 20:54 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Strides Pharma Science Limited is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aditya Khemka | Ambit Capital |
| Harith Ahamed | Avendus Spark |
| Prakash Agarwal | Axis Capital Limited |